Seven ranked. Thirteen worth noting. Eight editions a day. Read in three minutes. Forwarded in under one.
Also worth noting
M&A Gilead cleared regulatory approvals for Arcellx. CAR-T is now a settled acquisition category. Smaller cell-therapy shops are on a clock.
Funding KKR deployed $11B in Asia data centers. The real infrastructure supercycle is regional, not domestic. Other mega-funds will explain why they moved slower.
M&A Toyota's tender offer for Toyota Industries succeeded. The OEM just tightened vertical supply ownership. Independent Tier-1s just watched their leverage erode.
Earnings Scholastic announced $200M share repurchase. Educational publishing cash is real. The question is whether management sees headwinds coming that make holding capital worse than returning it.
Rebrand Bradley Radoff & Jumana Capital disclosed 7.6% in Genesco. Retail apparel activism is back. The category must have been written down enough to justify a fix.
Trend Lone Pine Capital made major portfolio shifts in latest 13F. When mega-funds rotate, smaller allocators follow. Track the names they are building, not the ones they are trimming.
Funding Renaissance Technologies opened a new $178.2M position in Eli Lilly. Quant mega-funds do not build positions this size in mature pharma without a tactical reason.
Launch Blackstone is eyeing a $2B IPO for a data-center acquisition firm. Infrastructure SPACs are dead. The new model is public roll-ups with institutional validation.
M&A GIP in talks to acquire Aligned Data Centers. Mega-fund infrastructure consolidation is now predictable. The next buyer is already queuing up.
Trend Institutional investors favored XRP. Crypto fund flows hit $224M. When institutions choose the asset that retail abandoned, the narrative is shifting faster than price.
Funding Lisata Therapeutics noted that Kuva Labs is seeking new financing. The tender offer has not commenced. Translation: the first bid was too low to accept.
Rebrand An activist investor targeted Bill. Payments software is now cheap enough for activist interest. Infrastructure-adjacent SaaS is the new hunting ground.
M&A Forian faces a $2.17 per-share tender. Biotech retail capitulation is priced in. Small-cap public biologics are now a liquidity disadvantage, not an advantage.